OMER Earnings

OMER reported its earnings on 2026-05-13, showcasing a revenue of 9.89M against an estimate of 700.00K, resulting in a 1313.29% surprise. The EPS was -0.24, surpassing the expected -0.4 by 40%. The stock experienced a -7.65% price change on the earnings day and a -16.76% change over the next five days, reflecting market reactions to the results.

Following OMER's earnings announcement on 2026-05-13, the stock price moved by -7.65% on the day of the release. Over the subsequent five days, it saw a -16.76% change. Historically, OMER's stock price tends to shift by an average of 9.62% in the 10 days leading up to earnings and 4.06% in the 10 days following, providing insight into potential market.

For , analysts estimate OMER's annual revenue to reach , while the EPS is projected at . These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between OMER's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, OMER's stock price typically moves by 9.62% in the 10 days before its earnings and 4.06% in the 10 days after. For the upcoming earnings, analysts expect an EPS of and revenue of .

The earnings call reflects strong financial performance, particularly with the YARTEMLEA launch driving significant revenue. Positive feedback from hematological oncologists and the anticipation of YARTEMLEA becoming a standard of care are encouraging. The share repurchase program and upfront cash from Novo Nordisk further bolster financial health. However, the lack of specific patient data and management's avoidance of certain disclosures could raise minor concerns. Overall, the positive aspects, including strong revenue and optimistic guidance, outweigh the negatives, suggesting a positive stock price movement.